Lilly's EloraTZP Brought Up to 77% of Adults With Diabetes to Normal Blood Sugar in Phase 2 Trial
Eli Lilly's experimental drug EloraTZP showed promising results in a Phase 2 trial, with up to 77% of adults with type 2 diabetes and obesity achieving normal blood sugar levels and 60% no longer meeting obesity criteria after 48 weeks. Participants in the best-performing group lost an average of 54.1 pounds, or 23.3% of their body weight. The trial did not test long-term safety or results after stopping the drug.
How this was made

The 30-second read
Why it matters
The new data add responder endpoints tied to diabetes control (normal blood sugar) and obesity status (moving out of obesity criteria), but the article stresses Phase 2-only evidence, undefined “normal” thresholds, and notable side-effect-driven discontinuations.
Market read
Traders may update expectations for Lilly’s obesity and diabetes pipeline based on incremental Phase 2 efficacy endpoints, while discounting for Phase 3 uncertainty and tolerability risk.
What to watch
The article notes the trial did not assess durability after stopping or whether patients could reduce diabetes meds, which are key for long-term value and payer impact.
Background
EloraTZP is an investigational combination pairing eloralintide (amylin receptor targeting) with tirzepatide (GLP-1/GIP), with Lilly presenting Phase 2 results at ObesityWeek 2026.
Ticker impact
Eli Lilly presented new Phase 2 data for EloraTZP at ObesityWeek, reporting up to 77% reaching normal blood sugar after 48 weeks.
Likely modest positive bias for sentiment around the program, tempered by the article’s emphasis on Phase 2 limitations and meaningful discontinuation from side effects.
The article discloses fresh, company-presented outcomes (normal blood sugar and moving out of obesity criteria) plus quantified tolerability (combination discontinuation up to 27%) and lack of Phase 3 confirmation.
Market effects
Reinforces investor focus on next-gen obesity and diabetes combinations (amylin plus incretin pathways) and the importance of tolerability versus efficacy in read-throughs.
Primarily US large-cap biotech sentiment via Lilly’s pipeline update; limited direct regional spillover.
ObesityWeek is international, but the actionable signal is company-specific clinical progress rather than a global policy or supply shock.
Counterpoint
High “up to” responder rates may not translate to broader populations, and the combination’s discontinuation risk could limit adoption even if Phase 3 confirms efficacy.
Key entities
- companyEli Lilly
Presented new Phase 2 EloraTZP outcomes at ObesityWeek, including responder rates for normal blood sugar and obesity criteria, plus tolerability metrics.
- drug_programEloraTZP
Investigational combination of eloralintide plus tirzepatide, studied in a Phase 2b trial over 48 weeks.
- conferenceObesityWeek 2026
Venue where Lilly presented the updated Phase 2 data on Nov. 15, 2026.

